GRIN Therapeutics, Inc., a leader in the development of targeted disease-specific therapies for serious neurodevelopmental disorders, today announced that it has dosed the first patient in its global ...
Northwestern University scientists have uncovered a hidden molecular "control switch" inside a protein that helps the body ...
Enliven Therapeutics, Inc. (Enliven or the Company) , a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced positive ...
Rezolute, Inc. is downgraded to a Sell after its phase 3 sunRIZE trial for congenital hyperinsulinism failed. Learn more about RZLT stock here.
Northwestern University scientists have uncovered a hidden molecular "control switch" inside a protein that helps the body ...
Vividion announces publication on discovery and preclinical study of small molecules activating KEAP1 via a covalent molecular glue to degrade NRF2.
MedPage Today on MSN
New drug approved for hypertrophic cardiomyopathy
The FDA on Friday approved aficamten (Myqorzo) for symptomatic obstructive hypertrophic cardiomyopathy (HCM), drugmaker Cytokinetics announced.
At the recent ELRIG Drug Discovery conference, Technology Networks<i/> spoke with Dr. Kundan Sharma to learn more about how cell-free expression platforms are transforming membrane protein research.
AZoLifeSciences on MSN
Hidden molecular control switch uncovered inside TRPM5 protein
Northwestern University scientists have uncovered a hidden molecular "control switch" inside a protein that helps the body sense taste, control blood sugar and defend the gut.
Cytokinetics ( (CYTK) ) just unveiled an announcement.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback